B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo therapy offers new hope for relapsed leukemia patients
Disease control Recruiting nowThis early-stage study tests a two-step treatment for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard therapies. First, patients receive donor immune cells (CAR T cells) followed by a stem cell transplant, then a second dose of donor…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Off-the-Shelf cell therapy takes on relapsed blood cancers
Disease control Recruiting nowThis early-phase study tests azer-cel, a ready-made CAR T cell therapy, in adults with non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to check safety and how well the therapy works. About 135 particip…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
Personalized chemo boosts CAR T-Cell success in childhood leukemia trial
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New CAR-T therapy offers hope for children with hard-to-treat leukemia and lymphoma
Disease control Recruiting nowThis study tests a new type of immune cell therapy (CAR-T) for children and teens whose B-cell leukemia or lymphoma has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target and kill cancer cells. The goal is to see…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New drug trial offers hope for young cancer patients
Disease control Recruiting nowThis study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
Donor immune cells offer new hope for kids with tough leukemia
Disease control Recruiting nowThis early-stage trial tests a new treatment for children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to target and kill cancer cells. …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New CAR t-cell combo shows promise for tough leukemia
Disease control Recruiting nowThis study tests two different CAR T-cell treatments for children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
New CAR-T therapy CLIC-2201 enters human trials for Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cell…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
Second-Chance CAR-T: Off-Spec therapy tested for blood cancers
Disease control Recruiting nowThis study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose CAR-T cell therapy didn't quite meet commercial quality standards. Researchers want to see if this slightly off-spec treatment is still safe and effective. About 200 participa…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Engineered donor cells take on tough leukemia in early trial
Disease control Recruiting nowThis study tests a new treatment called UCART22 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapies. UCART22 uses immune cells from a healthy donor that are specially designed to find and attack ca…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New 'Sandwich' therapy aims to beat leukemia without donor transplant
Disease control Recruiting nowThis early study tests a new approach for adults with B-cell acute lymphoblastic leukemia who cannot or choose not to have a donor stem cell transplant. The treatment combines the drug blinatumomab with the patient's own stem cells in a 'sandwich' strategy to reduce relapse risk.…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug cocktail IoVeX aims to tame relapsed leukemia
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for people whose B-cell acute lymphoblastic leukemia has returned. About 28 children and adults will receive the drugs over one or two 28-day cyc…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for older leukemia patients: easier treatment combo enters trial
Disease control Recruiting nowThis study tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL) in people aged 60 and older, or younger adults who cannot handle strong chemotherapy. The treatment combines a drug called blinatumomab, given as a shot under the skin, with a milder chemotherapy. The…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug YK012 shows promise in early trial for blood cancer
Disease control Recruiting nowThis study tests a new drug, YK012, in people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The goal is to check if the drug is safe and to see how well it works against the cancer. About 46 participants will take part in this early-phase trial.
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New cell therapy SYNCAR-100 tested in Tough-to-Treat leukemia
Disease control Recruiting nowThis early study tests a new treatment called SYNCAR-100 in 16 adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapy. The main goal is to check safety and side effects, while also seeing if the treatment c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New hope for hard-to-treat leukemias? early trial combines four drugs
Disease control Recruiting nowThis early-phase study tests a new drug (ABL001) combined with three other medicines (dasatinib, prednisone, and blinatumomab) for people with B-cell acute lymphoblastic leukemia or chronic myeloid leukemia that has a specific genetic marker (BCR-ABL positive). The main goal is t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New gene therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Double CAR t attack: new hope for kids with tough leukemia
Disease control Recruiting nowThis study tests a combination of two types of engineered immune cells (CAR T cells) in children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to treatment. The goal is to see if giving both anti-CD19 and anti-CD22 CAR T cells to…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
New combo therapy aims to keep cancer-fighting cells from burning out
Disease control Recruiting nowThis study looks at whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in people with relapsed or refractory B-cell acute lymphoblastic leukemia. About 213 children and young adults will be randomly assigned to receive either sta…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
New Dual-Target CAR t therapy offers hope for children with Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It is for children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can shr…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
Study seeks to solve vaccine puzzle for kids treated for blood cancer
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) who received blinatumomab for B-cell acute lymphoblastic leukemia still have protection from their childhood vaccines. Researchers will test antibody levels for diseases like tetanus, hepatitis B, and measles. I…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated May 11, 2026 20:54 UTC